Skip to main content

Advertisement

SpringerLink
Log in

Association of P53 (−16ins-Pro) Haplotype with the Decreased Risk of Differentiated Thyroid Carcinoma in Iranian-Azeri Patients

  • Research
  • Published:
Pathology & Oncology Research

Abstract

Association of P53 polymorphisms with the increased risk of various cancers has been investigated in numerous studies. However, the results were conflicting and no polymorphism has been determined as a definite risk factor. It is likely that the study of P53 combined genotypes and haplotypes may be more useful than individual polymorphisms. Thus, in this study, we analyzed the associations of intron 3 Ins16bp and exon 4 Arg72Pro polymorphisms, as well as their combined genotypes and haplotypes with the risk of differentiated thyroid carcinoma in Iranian-Azeri patients. This case–control study was performed on 84 Iranian Azeri patients with differentiated thyroid carcinoma and 150 healthy subjects. Intron 3 genotype was determined using PCR products analysis on polyacrylamide gels and AS-PCR was used for genotyping Arg72Pro polymorphism. The javastat online statistics package software and SHEsis program were applied for data analysis. There was no significant difference in genotype frequencies of both two polymorphisms between cases and controls. However, the (−16ins/−16ins) (Arg/Pro) genotype combination had a noticeable but not significant association with decreased risk of thyroid cancer development (OR = 0.497 95%CI: 0.209–1.168 P =0.080) and also the frequency of (−16ins-Pro) haplotype was significantly higher in controls rather than patients (OR = 0.543 95%CI: 0.326–0.903 P =0.018). In our study, there was association between (−16ins-Pro) haplotype with decreased risk of differentiated thyroid carcinoma development in Iranian-Azeri patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stegh AH (2012) Targeting the P53 signaling pathway in cancer therapy—The promises, challenges, and perils. Expert Opin Ther Targets 16(1):67–83

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Machado-Silva A, Perrier S, Bourdon JC (2010) P53 family members in cancer diagnosis and treatment. Semin Cancer Biol 20:57–62

    Article  CAS  PubMed  Google Scholar 

  3. Whibley C, Pharoah PD, Hollstein M (2009) P53 polymorphisms: cancer implications. Nat Rev Cancer 9:95–107

    Article  CAS  PubMed  Google Scholar 

  4. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR (2002) P53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94:681–690

    Article  CAS  PubMed  Google Scholar 

  5. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutiérrez-Enríquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F (2004) A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23:1954–1956

    Article  CAS  PubMed  Google Scholar 

  6. Faghani M, Ghasemi FM, Nikhbakht M, Salehi M (2011) TP53 PIN3 polymorphism associated with breast cancer risk in Iranian women. Indian J Cancer 48(3):298–302

    Article  CAS  PubMed  Google Scholar 

  7. Hu Z, Li X, Qu X, He Y, Ring BZ, Song E, Su L (2010) Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. Carcinogenesis 31(4):643–647

    Article  CAS  PubMed  Google Scholar 

  8. Runnebaum IB, Tong XW, König R, Zhao H, Körner K, Atkinson EN, Kreienberg R, Kieback DG, Hong Z (1995) P53- based blood test for P53PIN3 and risk for sporadic ovarian cancer. Lancet 1345(8955):994–994

    Article  Google Scholar 

  9. Alawadi S, Ghabreau L, Alsaleh M, Abdulaziz Z, Rafeek M, Akil N, Alkhalaf M (2011) 53 gene polymorphisms and breast cancer risk in Arab women. Med Oncol 28(3):709–715

    Article  PubMed  Google Scholar 

  10. Sagne C, Marcel V, Amadou A, Hainaut P, Olivier M, Hall J (2013) A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. Cell Death Dis 14(4):e492

  11. Dumont P, Leu JI, Della Pietra AC, George DL 3rd, Murphy M (2003) The codon 72 polymorphic variants of P53 have markedly different apoptotic potential. Nat Genet 33:357–365

    Article  CAS  PubMed  Google Scholar 

  12. Papadakis EN, Dokianakis DN, Spandidos DA (2000) p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3:389–92

    Article  CAS  PubMed  Google Scholar 

  13. Brenna SM, Silva ID, Zeferino LC, Pereira JS, Martinez EZ, Syrjänen KJ (2004) Prognostic value of P53 codon 72 polymorphism in invasive cervical cancer in Brazil. Gynecol Oncol 93:374–380

    Article  CAS  PubMed  Google Scholar 

  14. Matakidou A, Eisen T, Houlston RS (2003) TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 18:377–385

    Article  CAS  PubMed  Google Scholar 

  15. Hou J, Jiang Y, Tang W, Jia S (2013) P53 codon 72 polymorphism and breast cancer risk: a meta-analysis. Exp Ther Med 5(5):1397–1402

    PubMed Central  CAS  PubMed  Google Scholar 

  16. Sipos JA, Mazzaferri EL (2010) Thyroid cancer epidemiology and prognostic variables. Clin Oncol 22:395–404

    Article  CAS  Google Scholar 

  17. Legakis I, Syrigos K (2011) Recent advances in molecular diagnosis of thyroid cancer. J Thyroid Res 2011:384213

    Article  PubMed Central  PubMed  Google Scholar 

  18. Antico Arciuch VG, Russo MA, Dima M, Kang KS, Dasrath F, Liao XH, Refetoff S, Montagna C, Di Cristofano A (2011) Thyrocyte-specific inactivation of P53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget 2(12):1109–26

    PubMed  Google Scholar 

  19. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA (1993) Gene P53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91(4):1753–60

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Marcel V, Tran PL, Sagne C, Martel-Planche G, Vaslin L, Teulade-Fichou MP, Hall J, Mergny JL, Hainaut P, Van Dyck E (2011) G-quadruplex structures in TP53 intron 3: role in alternative splicing and in production of p53 mRNA isoforms. Carcinogenesis 32(3):271–8

    Article  CAS  PubMed  Google Scholar 

  21. Dai S, Mao C, Jiang L, Wang G, Cheng H (2009) P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case–control studies. Hum Genet 125:633–8

    Article  CAS  PubMed  Google Scholar 

  22. Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA (2002) p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 179(2):175–83

    Article  CAS  PubMed  Google Scholar 

  23. de Souza LG, de Lima JM, da Silva IDCG, Forones NM (2009) P53 Arg72Pro polymorphism in gastric cancer patients. J Gastrointest Cancer 40:41–5

    Article  CAS  Google Scholar 

  24. Reis AA, Silva DM, Curado MP, da Cruz AD (2010) Involvement of CYP1A1, GST, 72TP53 polymorphisms in the pathogenesis of thyroid nodules. Genet Mol Res 9(4):2222–9

    Article  CAS  PubMed  Google Scholar 

  25. Aral C, Çaglayan S, Özisik G, Massoumilary S, Sönmez O, Akkiprik M, Baloğlu H, Özata M, Özer A (2007) The association of P53 codon 72 polymorphism with thyroid cancer in turkish patients. Marmara Med J 20:1–5

    Google Scholar 

  26. Boltze C, Roessner A, Landt O, Szibor R, Peters B, Schneider-Stock R (2002) Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undiferentiated thyroid carcinoma. Int J Oncol 21:1151–1154

    CAS  PubMed  Google Scholar 

  27. Wu B, Guo D, Guo Y (2014) Association between p53 Arg72Pro polymorphism and thyroid cancer risk: a meta-analysis. Tumour Biol 35(1):561–5

    Article  CAS  PubMed  Google Scholar 

  28. Trifa F, Karray-Chouayekh S, Mabrouk I, Baccouche S, Khabir A, Sellami-Boudawara T, Gargouri A, Mokdad-Gargouri R (2010) Haplotype analysis of P53 polymorphisms: Arg72Pro, Ins16bp and G13964C inTunisian patients with familial or sporadic breast cancer. Cancer Epidemiol 34:184–188

    Article  CAS  PubMed  Google Scholar 

  29. Patel KR, Vajaria BN, Begum R, Shah FD, Patel JB, Shukla SN, Patel PS (2013) Association between p53 gene variants and oral cancer susceptibility in population from Gujarat, west India. Asian Pac J Cancer Prev 14(2):1093–1100

    Article  PubMed  Google Scholar 

  30. Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, Schmitt F (2008) Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 8:32

    Article  PubMed Central  PubMed  Google Scholar 

  31. Buyru N, Altinisik J, Demokan S, Dalay N (2007) P53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect Prev 31:207–13

    Article  CAS  PubMed  Google Scholar 

  32. Själander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L (1996) p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17(6):1313–1316

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Imam Reza and Noor-E-Nejat hospitals staffs for their cooperation in sample and clinicopathological data collection procedure.

Declaration of interest

There is no conflict of interest for this paper.

Author information

Authors and Affiliations

  1. Department of Biology, Tabriz University, Tabriz, Iran

    Roghayeh Dehghan, Mohammad Ali Hosseinpour Feizi, Esmaeil Babaei, Ayda Sedaei, Parvin Azarfam & Masoumeh Nemati

  2. Department of Biology, Azarbaijan Shahid Madani University, Tabriz, Iran

    Nasser Pouladi

  3. Department of thorax surgery, Noor-E-Nejat hospital, Tabriz, Iran

    Vahid Montazeri

  4. Department of pathology, Tabriz University of Medical Sciences, Tabriz, Iran

    Ashraf Fakhrjoo

Authors
  1. Roghayeh Dehghan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammad Ali Hosseinpour Feizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nasser Pouladi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Esmaeil Babaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vahid Montazeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ashraf Fakhrjoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ayda Sedaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Parvin Azarfam
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masoumeh Nemati
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Ali Hosseinpour Feizi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dehghan, R., Hosseinpour Feizi, M.A., Pouladi, N. et al. Association of P53 (−16ins-Pro) Haplotype with the Decreased Risk of Differentiated Thyroid Carcinoma in Iranian-Azeri Patients. Pathol. Oncol. Res. 21, 449–454 (2015). https://doi.org/10.1007/s12253-014-9846-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-014-9846-y

Keywords

Search

Navigation